Form 4: Unity Biotechnology CLO Alexander Hieu Nguyen Reports Stock Transactions
SEC Form 4 Filing
Alexander Hieu Nguyen, CLO and Head of Operations at Unity Biotechnology, reports the sale and acquisition of company stock and stock options.
Summary
- Alexander Hieu Nguyen, the Chief Legal Officer and Head of Operations at Unity Biotechnology, filed a Form 4 detailing changes in beneficial ownership.
- On March 27, 2025, Nguyen sold 1,954 shares of common stock at $1.16 per share to cover tax withholding obligations related to vesting Restricted Stock Units (RSUs).
- On March 28, 2025, Nguyen acquired 44,000 RSUs that vested upon meeting certain performance criteria.
- Nguyen also acquired an option to purchase 73,000 shares of common stock at an exercise price of $1.67, granted on January 30, 2024.
- Half of these options vested on March 28, 2025, upon meeting performance criteria, with the remaining options vesting in 12 equal monthly installments.
Sentiment
Score: 5
Explanation: The sentiment is neutral. The transactions are related to standard compensation practices (vesting and tax obligations). There's no clear indication of positive or negative sentiment towards the company's future prospects.
Positives
- The vesting of RSUs and stock options indicates that performance criteria were met, which could be seen as a positive sign for the company's progress.
Negatives
- The sale of 1,954 shares, even if for tax obligations, could be interpreted negatively by some investors.
Risks
- The vesting of a significant number of RSUs and options could potentially dilute existing shareholders' equity.
Future Outlook
The remaining half of the 73,000 stock options will vest in 12 successive, equal monthly installments, subject to continued service.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Investors often monitor these filings to gauge management's sentiment and confidence in the company's prospects.
Stakeholder Impact
- The vesting of RSUs and options could dilute existing shareholders' equity.
Key Dates
| Date | Description |
|---|---|
| January 30, 2024 | Board of Directors granted 44,000 RSUs and an option to purchase 73,000 shares. |
| March 27, 2025 | Nguyen sold 1,954 shares of common stock at $1.16 per share. |
| March 28, 2025 | 44,000 RSUs vested upon meeting certain performance criteria; half of the 73,000 stock options vested. |
| March 31, 2025 | Date of Form 4 filing. |
| March 27, 2035 | Expiration date of the stock options. |
Keywords
Form 4, beneficial ownership, stock options, restricted stock units, Unity Biotechnology, UBX, Nguyen, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.